PMP22 and hereditary neuropathy with liability to pressure palsies: As heterozygous deletion of PMP22 (leads to downregulation of PMP22) cause HNPP (31), a rationale therapeutic approach for CMT1A would be normalizing PMP22 gene expression to physiological level.